Twist Bioscience taps public markets for $250M share sale
What's the deal? Twist Bioscience (TWST) launched an underwritten public offering of $250 million of common stock. The DNA synthesis company is selling all the shares itself and granted underwriters a 30-day option to buy up to an additional $37.5 million.
What's the endgame? Proceeds will fund research and development, manufacturing capacity expansion, and product offerings, alongside general corporate purposes.
The signal: At $250 million, this ranks among the largest post-IPO equity raises in US health, sitting in the 93rd percentile of more than 3,800 comparable rounds. The size signals Twist is leaning on public markets to bankroll scaling ambitions rather than dilute through smaller top-ups.
Read more: MSN
Image credit: USDAgov
Source: dealroom
